JDD February 2025 Editor’s Picks
The February 2025 issue of the Journal of Drugs in Dermatology brings a fresh wave of clinical insights and innovative research to the dermatology community. This edition highlights new perspectives on minoxidil adherence, groundbreaking findings in keloid and hypertrophic scar risk factors, and expert consensus on deucravacitinib for plaque psoriasis.
Readers will also discover updates on non- …
The February 2025 issue of the Journal of Drugs in Dermatology brings a fresh wave of clinical insights and innovative research to the dermatology community. This edition highlights new perspectives on minoxidil adherence, groundbreaking findings in keloid and hypertrophic scar risk factors, and expert consensus on deucravacitinib for plaque psoriasis.
Readers will also discover updates on non- … 
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a … 
At the Skin of Color Update 2024, we had the honor to learn from Dr. Rebecca Vasquez, Associate Professor at UT Southwestern Medical Center, regarding the evolving field of vitiligo management. Vitiligo affects between 0.5% to 2% of the global population, with no racial or gender preference, yet it carries a significant psychological burden for affected individuals.1 Dr. Vasquez emphasized that vi … 
As dermatologists, we recognize that chronic itch is a complex and often debilitating condition that significantly impacts our patients' quality of life, affecting their physical health, mental well-being, and daily activities. Chronic itch can be especially challenging to diagnose and treat, particularly in patients with skin of color, who may experience unique clinical manifestations and complic … 